Novo Nordisk rebranded as "Novo" for day-to-day use, retaining its legal name Novo Nordisk A/S, with the tagline "Lasting Health Starts Now" and a cultural framework called "The Novo Way," as president and CEO Mike Doustdar made the rebrand his first major public strategic statement. Novo also announced an AI drug discovery collaboration with Anthropic and struck a $1.4 billion macrocycle partnership, all within 72 hours. Bayer received its third FDA indication for KERENDIA, the first new CKD treatment for Type 1 diabetes in 30 years. GSK made its second Chimagen acquisition, acquiring a next-generation T-cell engager. Sanofi offloaded 20 mature medicines to Cheplapharm in the largest portfolio simplification move it has made to date. Novo will provide a detailed overview of its updated corporate strategy at its Capital Markets Day on September 21 in London.